Spotlight On... Suffering Eleven Bio gets a delisting notice from Nasdaq; Omeros spikes on orphan status, PhIII plans; Rigel names new CMO; and more...

After back-to-back clinical disasters pushed Eleven Biotherapeutics ($EBIO) into penny stock territory, Nasdaq says it's time to get squared away or move off the exchange. The Cambridge, MA-based biotech addressed the delisting notice from Nasdaq in an SEC filing, noting that its stock is trading under $1 a share and that stockholders' equity did not comply with the minimum stockholders' equity requirement of $5,000,000. The biotech now has 180 days to regain compliance with Nasdaq rules. SEC filing

@FierceBiotech: Eyeing the U.S. market, TiGenix touts 52-wk data from PhIII stem cell trial. Story | Follow @FierceBiotech

@JohnCFierce: I have a gut feeling that UC and The Broad are going to settle up on CRISPR. Excellent summary from STAT story | Follow @JohnCFierce

> Shares of Omeros ($OMER) were buoyed on Tuesday after the biotech reported that it had won orphan drug status and launched a late-stage program for its kidney therapy. Story

> Rigel Pharmaceuticals ($RIGL) named Anne-Marie Duliege to the role of chief medical officer, replacing Elliott Grossbard, who is retiring after 14 years with the company. Release

> Epizyme ($EPZM) outlined plans for the next 5 years of its business, looking to transition into a commercial operation and prepare for the potential approval of its lead cancer drug. More

> Sterop, a Belgian drugmaker, is accused of supplying ephedrine to Mexican drug cartels to be used in the production of methamphetamine. Story

> AstraZeneca's ($AZN) in-development cancer therapy MEDI-551 picked up the FDA's orphan drug designation for its potential in neuromyelitis optica, a rare autoimmune disorder. News

Medical Device News

@FierceMedDev: ICYMI yesterday: J&J's Ethicon to buy NeuWave for soft-tissue, microwave ablation for cancer. Article | Follow @FierceMedDev

@VarunSaxena2: Toyota developing wearable device to improve mobility for the blind. Report | Follow @VarunSaxena2

@EmilyWFierce: Duke University teams with NC State for new cancer drug development project in canines. FierceAnimalHealth story | Follow @EmilyWFierce

> BD forms $500M JV with private equity firm Apax to house ailing respiratory biz. Report

> Agilent to lay down $80M for large stake in sequencing company Lasergen. Story

> Canon in exclusive negotiations to acquire Toshiba Medical Systems, likely for around $6B. Article

Pharma News

@FiercePharma: South Korea's Green Cross to supply Americas with flu vaccine in $32M deal. FierceVaccines item | Follow @FiercePharma

@EricPFierce: More biologics manufacturing capacity comes online in the U.S. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Amgen is eyeing heftier deals, but so are its biggest rivals. Story | Follow @CarlyHFierce

> Orexigen takes another body blow from ill-fated Contrave trial. More

> With FDA settlement, tiny Amarin creates opening for pharma in off-label marketing. Story

> Surprise proposal: Medicare wants to jump on the value-based pricing bandwagon. Article

Pharma Marketing News

> Allergan rolls out third round of Linzess ads, targeting patients fed up with OTC meds. Report

> Fake smiles star in Otsuka and Lundbeck's DTC push for Rexulti in depression. Story

> Ill-fated Contrave trial piles more hurt on Orexigen. Item

> AbbVie's Humira, Pfizer's Lyrica kick off 2016 with hefty TV ad spend. Article

> Blind Pfizer sales rep gets her chance to argue for a car and driver in court. More

Biotech Research News

> MIT team spotlights role of amino acids in building tumor cells. Item

> Single gene mutation linked with significantly reduced heart attack risk. Report

> Mouse, tissue tests confirm a new pathway for insulin resistance in diabetes. Story

> Karolinska: Nanoparticle tech opens up new drug, vaccine targets. More

> Mount Sinai: CDK4/ARK5 inhibitor could offer new treatment for multiple myeloma. Article

Vaccines News

> Sanofi digs into details on hastened Zika effort. Story

> Vaxart, Immunovaccine, Mayo Clinic jump onto Zika vaccine bandwagon. More

> South Korea's Green Cross to supply Americas with flu vaccine in $32M deal. Item

> Duke, NIAID track HIV evolution with eyes on creating a vaccine. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.